IMCC · IM Cannabis Corp.

This Nasdaq minimum bid price deficiency represents a HIGH material event for investors because it directly threatens the company’s continued listing on a U.S. national securities exchange — a critical factor for liquidity, institutional eligibility, and investor access. The notice stems solely from share price performance, not financial insolvency or regulatory violations, but reflects sustained market skepticism about IMC’s operational execution, profitability path, or growth prospects in its core Israel and Germany medical cannabis markets. While Nasdaq provides a clear remediation pathway — achieving $1.00+ for ten consecutive business days — the filing discloses no specific actions (e.g., reverse stock split proposal, capital raise, or strategic update) intended to address the deficiency, only a general statement that the company 'intends to monitor the closing bid price' and 'consider available options'. The forward-looking statements section underscores material risks including geopolitical instability in Israel and Eastern Europe, supply chain constraints, licensing uncertainty, and intense competition — all of which could impede timely recovery. Given the absence of earnings, financing, or governance disclosures in this filing, the delisting risk becomes the dominant near-term catalyst, with potential consequences including reduced analyst coverage, exclusion from major indices, and diminished access to U.S. capital markets if unresolved.